Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will discuss the scientific basis for treating Alzheimer's disease as a multi-protein disorder and highlight Annovis' approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial.
The announcement underscores a paradigm shift in Alzheimer's research, moving from single-target therapies to multi-protein interventions. Buntanetap, an investigational once-daily oral therapy, inhibits the translation of multiple neurotoxic proteins—including APP, amyloid beta, tau, alpha-synuclein, and TDP-43—through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
According to the company, this presentation at Fierce Biotech Week 2026 provides a platform to share preclinical and clinical data supporting buntanetap's potential. The event, known for gathering industry leaders, offers Annovis the opportunity to engage with key stakeholders and discuss the implications of targeting multiple pathways in Alzheimer's disease. The company's Phase 3 trial represents a critical step toward regulatory approval and commercial availability.
Annovis Bio, headquartered in Malvern, Pennsylvania, is dedicated to developing treatments for Alzheimer's and Parkinson's diseases. The company's focus on multiple neurotoxic proteins distinguishes it from competitors relying on single-target approaches. If successful, buntanetap could become a cornerstone therapy for Alzheimer's, a disease affecting millions worldwide with limited treatment options.
For more information about Annovis Bio and its pipeline, visit the company's website at www.annovisbio.com. Follow the company on LinkedIn, YouTube, and X for updates. The presentation at Fierce Biotech Week 2026 is expected to provide further insights into the scientific rationale and clinical progress of buntanetap.
